BioCentury | Jul 3, 2006
Company News

Chronogen, Tripos deal

...TRPS received an undisclosed milestone payment from Chronogen under a 2004 deal in which TRPS uses...
...2004 deal in which TRPS uses its chemistry technology to provide drug discovery services to Chronogen...
...see BioCentury, Jan. 19, 2004). The payment was triggered by a program entering preclinical development. Chronogen Inc....
BioCentury | May 1, 2006
Clinical News

CHGN111: Phase I/II start

...Chronogen will begin this week an open-label Canadian Phase I/II trial in 24 healthy volunteers. Chronogen Inc....
BioCentury | Jan 16, 2006
Company News

Chronogen management update

Chronogen Inc. , Montreal, Quebec Business: Cardiovascular, Cancer Hired: Jean-Marie Houle as VP of R&D, formerly an industry consultant WIR Staff...
BioCentury | Aug 1, 2005
Company News

Enobia Phase Inc. board of directors update

...Bouchard, VP of clinical development and regulatory affairs at Labopharm Inc.; Max Felhmann, CEO of Chronogen...
BioCentury | Jul 25, 2005
Company News

Chronogen scientific advisory board update

Chronogen Inc. , Montreal, Quebec Business: Cardiovascular, Cancer Appointed: Jean Davignon, director of hyperlipidemia and atherosclerosis research group at the Clinical Research Institute of Montreal, as chairman; Jean-Charles Fruchart, president elect at the International Society of...
BioCentury | Jul 11, 2005
Company News

Chronogen, Zambon Group S.p.A. deal

...and lipid disorders. Chronogen will use its phenotype-based in vivo assays to screen Inpharzam's library. Chronogen Inc....
BioCentury | Apr 18, 2005
Company News

Chronogen management update

Chronogen Inc. , Montreal, Quebec Business: Cardiovascular, Endocrine Hired: Pierre-Yves Desbiens as VP of finance and administration, formerly a senior investment advisor for life sciences at Fonds de Solidarite FTQ; and Pascal Puchois as VP of...
BioCentury | Jan 17, 2005
Company News

Chronogen, Sosei Co. Ltd. deal

...which may be suitable for indications other than those for which they were originally developed. Chronogen Inc....
BioCentury | Jan 11, 2005
Company News

Chronogen, Sosei screening deal

Chronogen (Montreal, Canada) will screen a compound library from Sosei (Tokyo:4565) using phenotype-based, in vivo screening technologies in the nematode C. elegans. The library from Sosei's Drug Reprofiling Platform is a collection of compounds that...
BioCentury | Nov 8, 2004
Company News

Chronogen management update

Chronogen Inc. , Montreal, Canada Business: Cancer, Cardiovascular Hired: Max Fehlmann as president and CEO, formerly director of R&D Zambon Group SpA WIR Staff...
Items per page:
1 - 10 of 25
BioCentury | Jul 3, 2006
Company News

Chronogen, Tripos deal

...TRPS received an undisclosed milestone payment from Chronogen under a 2004 deal in which TRPS uses...
...2004 deal in which TRPS uses its chemistry technology to provide drug discovery services to Chronogen...
...see BioCentury, Jan. 19, 2004). The payment was triggered by a program entering preclinical development. Chronogen Inc....
BioCentury | May 1, 2006
Clinical News

CHGN111: Phase I/II start

...Chronogen will begin this week an open-label Canadian Phase I/II trial in 24 healthy volunteers. Chronogen Inc....
BioCentury | Jan 16, 2006
Company News

Chronogen management update

Chronogen Inc. , Montreal, Quebec Business: Cardiovascular, Cancer Hired: Jean-Marie Houle as VP of R&D, formerly an industry consultant WIR Staff...
BioCentury | Aug 1, 2005
Company News

Enobia Phase Inc. board of directors update

...Bouchard, VP of clinical development and regulatory affairs at Labopharm Inc.; Max Felhmann, CEO of Chronogen...
BioCentury | Jul 25, 2005
Company News

Chronogen scientific advisory board update

Chronogen Inc. , Montreal, Quebec Business: Cardiovascular, Cancer Appointed: Jean Davignon, director of hyperlipidemia and atherosclerosis research group at the Clinical Research Institute of Montreal, as chairman; Jean-Charles Fruchart, president elect at the International Society of...
BioCentury | Jul 11, 2005
Company News

Chronogen, Zambon Group S.p.A. deal

...and lipid disorders. Chronogen will use its phenotype-based in vivo assays to screen Inpharzam's library. Chronogen Inc....
BioCentury | Apr 18, 2005
Company News

Chronogen management update

Chronogen Inc. , Montreal, Quebec Business: Cardiovascular, Endocrine Hired: Pierre-Yves Desbiens as VP of finance and administration, formerly a senior investment advisor for life sciences at Fonds de Solidarite FTQ; and Pascal Puchois as VP of...
BioCentury | Jan 17, 2005
Company News

Chronogen, Sosei Co. Ltd. deal

...which may be suitable for indications other than those for which they were originally developed. Chronogen Inc....
BioCentury | Jan 11, 2005
Company News

Chronogen, Sosei screening deal

Chronogen (Montreal, Canada) will screen a compound library from Sosei (Tokyo:4565) using phenotype-based, in vivo screening technologies in the nematode C. elegans. The library from Sosei's Drug Reprofiling Platform is a collection of compounds that...
BioCentury | Nov 8, 2004
Company News

Chronogen management update

Chronogen Inc. , Montreal, Canada Business: Cancer, Cardiovascular Hired: Max Fehlmann as president and CEO, formerly director of R&D Zambon Group SpA WIR Staff...
Items per page:
1 - 10 of 25